OBJECTIVE: To evaluate the safety and feasibility of N-butyl cyanoacrylate (N-BCA) embolization of percutaneous transhepatic portal venous access tract and to establish an appropriate technique. METHODS: 40 consecutive patients underwent percutaneous transhepatic portal venous intervention for various reasons. Embolization of percutaneous transhepatic portal venous access tract was performed after the procedure in all of the patients using N-BCA and Lipiodol® (Lipiodol Ultra Fluide; Laboratoire Guerbet, Aulnay-sous-Bois, France) mixture. Immediate ultrasonography and fluoroscopy were performed to evaluate perihepatic haematoma formation and unintended embolization of more than one segmental portal vein. Follow-up CT was performed, and haemoglobin and haematocrit levels were checked to evaluate the presence of bleeding. RESULTS: Immediate haemostasis was achieved in all of the patients, without development of perihepatic haematoma or unintended embolization of more than one segmental portal vein. Complete embolization of percutaneous access tract was confirmed in 39 out of 40 patients by CT. Seven patients showed decreased haemoglobin and haematocrit levels. Other complications included mild pain at the site of embolization and mild fever, which resolved after conservative management. 16 patients died during the follow-up period owing to progression of the underlying disease. CONCLUSION: Embolization of percutaneous transhepatic portal vein access tract with N-BCA is feasible and technically safe. With the appropriate technique, N-BCA can be safely used as an alternate embolic material since it is easy to use and inexpensive compared with other embolic materials. ADVANCES IN KNOWLEDGE: This is the first study to investigate the efficacy of N-BCA for percutaneous transhepatic portal venous access tract embolization.
OBJECTIVE: To evaluate the safety and feasibility of N-butyl cyanoacrylate (N-BCA) embolization of percutaneous transhepatic portal venous access tract and to establish an appropriate technique. METHODS: 40 consecutive patients underwent percutaneous transhepatic portal venous intervention for various reasons. Embolization of percutaneous transhepatic portal venous access tract was performed after the procedure in all of the patients using N-BCA and Lipiodol® (Lipiodol Ultra Fluide; Laboratoire Guerbet, Aulnay-sous-Bois, France) mixture. Immediate ultrasonography and fluoroscopy were performed to evaluate perihepatic haematoma formation and unintended embolization of more than one segmental portal vein. Follow-up CT was performed, and haemoglobin and haematocrit levels were checked to evaluate the presence of bleeding. RESULTS: Immediate haemostasis was achieved in all of the patients, without development of perihepatic haematoma or unintended embolization of more than one segmental portal vein. Complete embolization of percutaneous access tract was confirmed in 39 out of 40 patients by CT. Seven patients showed decreased haemoglobin and haematocrit levels. Other complications included mild pain at the site of embolization and mild fever, which resolved after conservative management. 16 patients died during the follow-up period owing to progression of the underlying disease. CONCLUSION: Embolization of percutaneous transhepatic portal vein access tract with N-BCA is feasible and technically safe. With the appropriate technique, N-BCA can be safely used as an alternate embolic material since it is easy to use and inexpensive compared with other embolic materials. ADVANCES IN KNOWLEDGE: This is the first study to investigate the efficacy of N-BCA for percutaneous transhepatic portal venous access tract embolization.
Authors: P Villiger; E A Ryan; R Owen; K O'Kelly; J Oberholzer; F Al Saif; T Kin; H Wang; I Larsen; S L Blitz; V Menon; P Senior; D L Bigam; B Paty; N M Kneteman; J R T Lakey; A M James Shapiro Journal: Am J Transplant Date: 2005-12 Impact factor: 8.086
Authors: Seung Hong Choi; Jeong Min Lee; Kyoung Ho Lee; Se Hyung Kim; Jae Young Lee; Joon Koo Han; Byung Ihn Choi Journal: AJR Am J Roentgenol Date: 2005-10 Impact factor: 3.959
Authors: Stuart M Lyon; Olaf Terhaar; Mark F Given; Helena M O'Dwyer; Frank P McGrath; Michael J Lee Journal: Cardiovasc Intervent Radiol Date: 2006 Nov-Dec Impact factor: 2.740
Authors: Sébastien Novellas; Alban Denys; Pierre Bize; Philippe Brunner; Jean Paul Motamedi; Jean Gugenheim; François-Xavier Caroli; Patrick Chevallier Journal: Cardiovasc Intervent Radiol Date: 2008-10-28 Impact factor: 2.740
Authors: Paolo Marra; Francesco Saverio Carbone; Luigi Augello; Ludovico Dulcetta; Riccardo Muglia; Pietro Andrea Bonaffini; Angelo Della Corte; Stephanie Steidler; Simone Gusmini; Giorgia Guazzarotti; Diego Palumbo; Massimo Venturini; Francesco De Cobelli; Sandro Sironi Journal: CVIR Endovasc Date: 2022-09-05